Pharmaceutical Executive
Brussels, Belgium-Tackling communicable diseases such as malaria and tuberculosis and making pregnancy and childbirth safer are priorities for the restructured Afghan health ministry, according to World Health Organization officials.
Brussels, Belgium-Tackling communicable diseases such as malaria and tuberculosis and making pregnancy and childbirth safer are priorities for the restructured Afghan health ministry, according to World Health Organization officials.
WHO, the United Nations Children's Fund, and non-governmental organizations have launched an appeal for nearly $130 million for immediate reconstruction of the war-torn country's health system, including vital medicines.
"Developing a functional healthcare system must be a top priority in the reconstruction of Afghanistan," says Dr. Mohammed Jama, WHO regional coordinator for the Afghanistan crisis. "As long as hundreds of thousands of Afghans continue to die from preventable diseases, a stable future for the country cannot be guaranteed."
A WHO mission to Afghanistan revealed a shortage of essential medicines that donations have only marginally improved in recent months. WHO is asking for $25 million to set up medical stores across the country.
Other priorities include the integrated management of childhood illnesses, the establishment of mental health services, and a safe blood transfusion service. "This package of basic services is designed to offer the basis of acceptable healthcare in Afghanistan," says Dr. Said Youssouf, WHO representative in Afghanistan.
The WHO appeal would amount to spending slightly more than $5 per person per year in Afghanistan. The organization estimates that $34 per person per year is needed for basic health services, but the present Afghani health infrastructure cannot handle such large amounts.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.